A research team has shown that T-cell responses specific to SARS-CoV-2 remain in the body after infection, providing immunity from mild re-infection.
List view / Grid view
Filter the results
Researchers demonstrate that the CARD8 protein plays a key role in regulating the inflammation that causes atherosclerosis and other inflammatory diseases.
COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes…
Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
Researchers have identified that autoreactive B cells and a protein that enables them to invade joints could be promising drug targets for the most common inflammatory arthritis.
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
Certain sensory neurons and Substance P are potential drug targets for the development of novel allergy preventions or treatments, according to scientists.
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.